197 related articles for article (PubMed ID: 7964514)
1. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.
de Hon FD; Ehlers M; Rose-John S; Ebeling SB; Bos HK; Aarden LA; Brakenhoff JP
J Exp Med; 1994 Dec; 180(6):2395-400. PubMed ID: 7964514
[TBL] [Abstract][Full Text] [Related]
2. Functional distinction of two regions of human interleukin 6 important for signal transduction via gp130.
de Hon FD; ten Boekel E; Herrman J; Clement C; Ehlers M; Taga T; Yasukawa K; Ohsugi Y; Kishimoto T; Rose-John S
Cytokine; 1995 Jul; 7(5):398-407. PubMed ID: 7578977
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
[TBL] [Abstract][Full Text] [Related]
4. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells.
Sporeno E; Savino R; Ciapponi L; Paonessa G; Cabibbo A; Lahm A; Pulkki K; Sun RX; Toniatti C; Klein B; Ciliberto G
Blood; 1996 Jun; 87(11):4510-9. PubMed ID: 8639818
[TBL] [Abstract][Full Text] [Related]
5. Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells.
Ehlers M; de Hon FD; Bos HK; Horsten U; Kurapkat G; van De Leur HS; Grötzinger J; Wollmer A; Brakenhoff JP; Rose-John S
J Biol Chem; 1995 Apr; 270(14):8158-63. PubMed ID: 7713920
[TBL] [Abstract][Full Text] [Related]
6. Rational design of a receptor super-antagonist of human interleukin-6.
Savino R; Ciapponi L; Lahm A; Demartis A; Cabibbo A; Toniatti C; Delmastro P; Altamura S; Ciliberto G
EMBO J; 1994 Dec; 13(24):5863-70. PubMed ID: 7813426
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface.
Salvati AL; Lahm A; Paonessa G; Ciliberto G; Toniatti C
J Biol Chem; 1995 May; 270(20):12242-9. PubMed ID: 7744875
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Fujita N; Tsuchiya M; Koishihara Y; Ohsugi Y; Nakagawa M
Leukemia; 1995 Apr; 9(4):711-8. PubMed ID: 7723407
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
10. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.
Diamant M; Hansen MB; Rieneck K; Svenson M; Yasukawa K; Bendtzen K
Leuk Res; 1996 Apr; 20(4):291-301. PubMed ID: 8642840
[TBL] [Abstract][Full Text] [Related]
11. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
J Clin Invest; 1995 Sep; 96(3):1319-27. PubMed ID: 7657807
[TBL] [Abstract][Full Text] [Related]
12. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
13. Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R).
Lust JA; Jelinek DF; Donovan KA; Frederick LA; Huntley BK; Braaten JK; Maihle NJ
Curr Top Microbiol Immunol; 1995; 194():199-206. PubMed ID: 7895493
[TBL] [Abstract][Full Text] [Related]
14. Development of a human interleukin-6 receptor antagonist.
Brakenhoff JP; de Hon FD; Fontaine V; ten Boekel E; Schooltink H; Rose-John S; Heinrich PC; Content J; Aarden LA
J Biol Chem; 1994 Jan; 269(1):86-93. PubMed ID: 8276883
[TBL] [Abstract][Full Text] [Related]
15. Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp.
Peppard JV; Loo P; Sills MA; Munster D; Pomponi SA; Wright AE
J Biol Chem; 1996 Mar; 271(13):7281-4. PubMed ID: 8631742
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2).
Van Riet I; De Greef C; Aharchi F; Woischwill C; De Waele M; Bakkus M; Lacor P; Schots R; Van Camp B
Leukemia; 1997 Feb; 11(2):284-93. PubMed ID: 9009094
[TBL] [Abstract][Full Text] [Related]
18. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells.
Burger R; Neipel F; Fleckenstein B; Savino R; Ciliberto G; Kalden JR; Gramatzki M
Blood; 1998 Mar; 91(6):1858-63. PubMed ID: 9490667
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a soluble IL-6 receptor alpha mutant C277D/H280I expressed in E.coli.
Duan J; Wang J; Cai X; Wang L; Liu H; Zou M
Biochem Mol Biol Int; 1997 May; 41(6):1101-8. PubMed ID: 9161704
[TBL] [Abstract][Full Text] [Related]
20. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura T; Udagawa N; Takahashi N; Miyaura C; Tanaka S; Yamada Y; Koishihara Y; Ohsugi Y; Kumaki K; Taga T
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11924-8. PubMed ID: 8265649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
